Literature DB >> 12442228

Evaluation of varicella immune status in an obstetric population in relation to place of birth.

Jay M Goldberg1, Harry K Ziel, Raoul Burchette.   

Abstract

Obstetric populations born in tropical or subtropical regions are likely to be seronegative for varicella virus; obstetric populations containing a large proportion of women born in tropical or subtropical regions will benefit greatly from being screened for varicella immunity. Physicians should therefore know the geographic origin of the community they serve and should consider testing varicella immunity in their obstetric patients born in tropical or subtropical regions. To ensure that passive immunization is received when indicated, physicians should obtain serostatus without relying on patients' recollection of their exposure to varicella virus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12442228     DOI: 10.1055/s-2002-35613

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  3 in total

1.  Validity of self-reported varicella disease history in pregnant women attending prenatal clinics.

Authors:  Barbara Watson; Rachel Civen; Meredith Reynolds; Karl Heath; Dana Perella; Tina Carbajal; Laurene Mascola; Aisha Jumaan; Laura Zimmerman; Abike James; Carlene Quashi; Scott Schmid
Journal:  Public Health Rep       Date:  2007 Jul-Aug       Impact factor: 2.792

2.  Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002.

Authors:  Gustavo H Dayan; María S Panero; Roberto Debbag; Ana Urquiza; Marta Molina; Susana Prieto; María Del Carmen Perego; Graciela Scagliotti; Diana Galimberti; Guillermo Carroli; Cristina Wolff; D Scott Schmid; Vladimir Loparev; Dalya Guris; Jane Seward
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  Seroprevalence of varicella antibodies among pregnant women in Lyon-France.

Authors:  M Saadatian-Elahi; Y Mekki; C Del Signore; B Lina; T Derrough; E Caulin; J Thierry; P Vanhems
Journal:  Eur J Epidemiol       Date:  2007-05-30       Impact factor: 12.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.